Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7306016 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL249120 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL12525029 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL12524998 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL14980914 | 0.82 | SMN1; SMN2 (0.38) | CYP2C9CYP2C19SMN1; SMN2GBA1CA2 | |
| SCHEMBL23841973 | 0.80 | CYP2C9 (0.41) | CYP2C9CYP2C19CA2GAAALDH1A1 | |
| SCHEMBL135940 | 0.77 | CA2 (0.40) | CYP2C9CYP2C19SMN1; SMN2CA2GAA | |
| SCHEMBL1443275 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 | |
| SCHEMBL14508491 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 | |
| SCHEMBL2798313 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219194-A1 | Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability | GEORGETOWN UNIVERSITY (US) | 2007-09-20 | — | — | US | claimed |
| US-9302120-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140148494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680132-B2 | Spiro-oxindole MDM2 antagonists | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| EP-2638046-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | The Regents of The University of Michigan (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8486989-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486989-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2012065022-A2 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010096371-A2 | HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | WO | disclosed |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7241796-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INC. (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | CYP2C9 3068/4885CYP2C19 2874/4885SMN1; SMN2 3088/4885 |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | CYP2C9 1405/4885CYP2C19 1381/4885SMN1; SMN2 2528/4885 |
| US-20070219194-A1 | Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability | TYRO3, PTMS, ACP1 | CYP2C9 1220/4885CYP2C19 2074/4885SMN1; SMN2 4607/4885 |
| US-20120122947-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | CYP2C9 3068/4885CYP2C19 2874/4885SMN1; SMN2 3088/4885 |
| US-20080045480-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | CYP2C9 1405/4885CYP2C19 1381/4885SMN1; SMN2 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.